The conflicts that generated rousing, unexpected, and occasionally contentious discussions at The International Comic Arts Forum’s (ICAF) 2017 conference this past weekend left attendees with hard but hopeful questions for future studies.
You too can join forces with a foundational Japanese manga creator, an award-winning Peruvian comics journalist, a Fantagraphics Books co-founder, a local cartoonist, a comic book rock star, and a league of international comics speakers.
Their elusive annual headquarters, the International Comic Arts Forum (ICAF) conference is free to attend and open to the public Nov. 2-4 in the HUB.
Reflections on a half-decade of service
In the fall of 1968, amid reactions to the Black Student Union’s sit-in at then-President Charles Odegaard’s offices and mounting unrest over the Vietnam War, freshman Gerald J. “Jerry” Baldasty entered his very first classroom at the UW.
Looking back on that time from his Gerberding Hall office, now-retiring Provost Baldasty marveled at the trajectory his UW career has taken, describing the almost-50-year journey from student to senior administrator as “transformative.”
“Coming from a working-class family in eastern Washington, who would have thought [I]’d ever become a provost or even a faculty member,” Baldasty said.
If you or someone you know is in immediate crisis, the National Sexual Assault Hotline, 800-656-HOPE is free, confidential, and available 24/7. In an emergency, call 911. More support resources are listed below.
Y’all, it’s been a week.
As obviously necessary as it has been to see the rank infection of systematic sexual abuse finally made visible, the last seven days of emotional pin-ball has left me teetering near the edge of perpetual exhaustion.
For those who participated in last week’s #metoo hashtag resurgence, either aloud or in silence, the unpredictable and inescapable reminders of something deeply, personally painful can be a double-edge sword.
Welcome to part four in the the saga of generic Concerta drug substitutions. The information in part three (part two and part one for those just joining us) raised several questions about pharmacy-level processes for generics that today’s column will start to answer. But first, a little housekeeping from last time.